Logo for University of Iowa Health Care This logo represents the University of Iowa Health Care

Our People

Elaine M. Binkley, portrait

Elaine M. Binkley, MD

Research Areas of Interest

  • Clinical and translational research in ocular melanoma and other posterior segment tumors
  • Clinical and translational research in von Hippel Lindau disease

Timothy M. Boyce, MD

Timothy M. Boyce, MD

Research Areas of Interest:

  • Clinical and translational research on ocular inflammatory and inherited retinal diseases

Terry Braun, portrait

Terry Braun

Research Areas of Interest

  • Developing software and bioinformatics to combine genomics and phenotypic data to study inherited eye disease.

H. Culver Boldt

H. Culver Boldt, MD

Research Areas of Interest

  • Clinical research on ocular melanoma and other ocular neoplasms
  • Clinical research on proliferative vitreoretinopathy, and age-related macular degeneration

Ian Han, MD

Ian C. Han, MD

Research Areas of Interest

  • Clinical research involving multimodal retinal imaging for the discovery of imaging-related biomarkers, genotype-phenotype correlations, and novel insights into pathophysiology
  • Translational research involving rat models of retinal degeneration for the development of gene and stem cell therapy for inherited eye disease

Robert Mullins

Rob Mullins, PhD

Research Areas of Interest

  • Utilizing human donor eyes to elucidate the cellular pathophysiology of diseases affecting the human retina and choroid in order to identify targets for treatment

Jonathan F. Russell, MD, PhD

Jonathan F. Russell, MD, PhD

Research Areas of Interest:

  • Wide field OCT angiography, particularly for diabetic retinopathy
  • Multimodal retinal imaging to enhance diagnosis and pathophysiologic understanding of choroidal and retinal disease
  • Clinical and translational research in complex retinal detachment, severe ocular trauma, pediatric retinal disease, uveitis, and ophthalmic genetics

Stephen R. Russell, portrait

Stephen R. Russell, MD

Research Areas of Interest

  • Research focus is on evaluating treatments for retinal disorders, typically through clinical trials.
  • Currently investigating gene replacement therapy to treat Leber's congenital amaurosis, as well as evaluating a light cycle inhibitor to treat the atrophic form of age-related macular degeneration termed geographic atrophy.
  • Currently working on electronic enhancement and sensory substitution approaches for low vision navigation and function.

Todd Scheetz, portrait

Todd Scheetz

Research Areas of Interest

  • Bioinformatic investigations into the genetics and biology underlying inherited eye disease.

Val C. Sheffield, MD, PhD

Val Sheffield, MD, PhD

Research Areas of Interest

  • Molecular genetics of monogenic disorders, as well as polygenic and multifactorial disorders

Elliott H. Sohn, portrait

Elliott H. Sohn, MD

Research Areas of Interest

  • Translational and clinical research related to retinal diseases, especially:
    • Age-related macular degeneration: from stem cell therapies to clinical trials to basic mechanisms of the pathophysiology especially related to genotype
    • Diabetic retinopathy: tissue and image-based analysis in mice and humans with focus on pathophysiology and treatment
    • Inherited macular dystrophies and retinal degenerations–gene and stem cell therapies in pigs and humans as well as phenotype-genotype correlations
    • Development of vitreoretinal surgical inventions and procedures

Edwin M. Stone, portrait

Edwin M. Stone, MD, PhD

Research Areas of Interest

  • Genetic basis and disease mechanisms of inherited retinal diseases
  • Affordable genetic testing with high sensitivity and specificity
  • Affordable gene and stem-cell therapies for ALL inherited retinal diseases
  • Web-based teaching of inherited retinal diseases
  • Deming-based continuous process improvement in academic medicine

Budd Tucker, portrait

Budd Tucker, PhD

Research Areas of Interest

  • Disease modeling of inherited eye diseases using patient derived stem cells
  • Treatment using genome editing, gene augmentation, retinal engineering, and cell transplantation.